Outlook Therapeutics, Inc.
NASDAQ:OTLK · NASDAQ Capital Market
+$0.12 today
Vol 41.29M · Avg 15.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
193.9%
avg -57.6%
ROIC
-2357.6%
avg -424.2%
ROA
-335.9%
avg -234.6%
Analysis
ROE is currently the strongest return metric at 193.9% versus its period average of -57.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Charles Jahr | President, Chief Executive Officer & Director | $603,062.00 | — | 53 | $800,000.00 | 1.94% |
Lawrence A. Kenyon | EVice President, Chief Financial Officer, Treasurer, Secretary & Director | $476,170.00 | — | 60 | $5,946.00 | 0.01% |
Surendra Sharma | Senior Vice President of Medical Affairs | — | — | — | — | — |
Joel Prieve | Senior Vice President of Licensing and M&A | — | — | — | — | — |
Jennifer Kissner | Senior Vice President of Clinical Development & Regulatory Affairs | — | — | — | — | — |
Jedd Comiskey | Senior Vice President - Head of Europe | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$12.31M
Sells
0
$0.00
Net Sentiment
+$12.31M
Net buying
Most Active
Sukhtian Ghiath M.
3 transactions
Analysis
Insiders reported 8 buys worth $12.31M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $12.31M. Sukhtian Ghiath M. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -16.0% | +21.0% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -16.0% over three years. Forward estimates point to Revenue at +21.0% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$194.78M
Equillium, Inc.
NASDAQ:EQ
$99.82M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages OTLK?
Outlook Therapeutics, Inc. (OTLK) lists 6 active executives. The top listed executive is Surendra Sharma, Senior Vice President of Medical Affairs.
Are OTLK insiders buying or selling?
Recent insider activity shows net buying of $135.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.